Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Torsade de pointes induced by N-acetylprocainamide.

M J Chow, A A Piergies, D J Bowsher

    Journal of the American College of Cardiology
    |September 1, 1984
    PubMed
    Summary

    N-Acetylprocainamide (NAPA), a Class III antiarrhythmic, can trigger torsade de pointes in susceptible patients. This case highlights the risk of NAPA-induced torsade de pointes even after initial favorable responses.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Common arterial trunk in a cat: a high-resolution morphological analysis with micro-computed tomography.

    Journal of veterinary cardiology : the official journal of the European Society of Veterinary Cardiology·2021
    Same author

    Measuring Biomarker Progress.

    Clinical pharmacology and therapeutics·2015
    Same author

    Mitochondrial pharmacology: its future is now.

    Clinical pharmacology and therapeutics·2014
    Same author

    In search of physiologically based distribution volume estimates for macromolecules.

    Clinical pharmacology and therapeutics·2012
    Same author

    Models of physiology and physiologically based models in clinical pharmacology.

    Clinical pharmacology and therapeutics·2012
    Same author

    [Hodgkin's disease demonstrated microscopically in the lymph nodes, prostate, kidney, periadrenal tissue, lung, pancreas, liver, and spleen].

    Gastroenterology·2010

    Area of Science:

    • Cardiology
    • Pharmacology
    • Clinical Medicine

    Background:

    • N-Acetylprocainamide (NAPA) is a Class III antiarrhythmic agent used for managing cardiac arrhythmias.
    • Previous antiarrhythmic drug therapy with quinidine and disopyramide had been associated with torsade de pointes in this patient.

    Observation:

    • An initial intravenous infusion of NAPA demonstrated a positive antiarrhythmic effect.
    • Prolongation of the QTc interval was observed, but the incremental lengthening was within expected parameters.
    • Subsequent oral administration of NAPA led to the development of torsade de pointes.

    Findings:

    • Torsade de pointes occurred during oral NAPA therapy at plasma concentrations previously tolerated during intravenous administration.
    • The patient exhibited a history of drug-induced torsade de pointes with other antiarrhythmic agents.

    Related Experiment Videos

    Implications:

    • This case underscores the potential for NAPA to induce torsade de pointes, even in patients with a history of similar events with other drugs.
    • Careful monitoring of plasma drug levels and QTc interval is crucial during NAPA therapy, especially with oral administration.
    • Individual patient susceptibility to proarrhythmic effects of antiarrhythmic drugs warrants consideration in treatment strategies.